Carey S. Roberts has sold
23,500 shares of
Ventas, Inc., resulting in a
2.1% fall since the last earnings report. Despite this, Ventas remains a strong
dividend stock with recent pricing of their
senior notes offering and issuance of a business update. The bio-tech company continues to form partnerships with financial corporations like
Mackenzie Financial Corp,
Toronto Dominion Bank, and
Ascent Group LLC. However, notable reductions in investment positions from
Royal Bank of Canada and
USS Investment Management Ltd were reported. Ventas also experienced internal changes, with
Robert F. Probst selling
17,374 shares. Highlighting their continued success, Ventas recently raised their
2025 Normalized FFO Guidance; however, Wall Street Zen downgraded the stock to
'Sell'. An established dividend stock, Ventas announced their most recent
quarterly dividend of US$0.48 per share, attracting more investors. The company projects promising results for its
2024 full year and increases in its stock dividend. It is proposing an amendment to increase authorized shares before a May stockholders meeting, a strategic move to strengthen Ventas' financial standing.
Ventas VTR News Analytics from Thu, 31 Oct 2024 07:00:00 GMT to Sun, 01 Jun 2025 00:14:52 GMT -
Rating 2.5
- Innovation 0
- Information 6
- Rumor -2
